Dendreon Corp fka DNDNQ

[iwfal]

Actually, the fact that GVAX can hold its own during its ramp up period against a relatively fast acting cytotoxic such as Taxotere dosing in the control arm is a somewhat postive factor for the final look.

You do not know that GVAX 'held its own'. What was the futility bar? Did they even have one? If not the DSMB safety limit is not likely to be tripped with so few events even with tax vs placebo.